Search Results
Found 1 results
510(k) Data Aggregation
(97 days)
GLUCOMETER ELITE DIABETES CARE SYSTEM (MODIFIED)
The GLUCOMETER ELITE® and the GLUCOMETER ELITE® XL Blood Glucose Meters are used with GLUCOMETER ELITE® Test Strips to measure glucose levels in whole blood from specimens taken from the fingers or an alternate puncture site within certain conditions. The GLUCOMETER ELITE Diabetes Care System is an overthe-counter (OTC) device used by persons with diabetes in a home setting and by healthcare professionals in healthcare facilities. The frequent monitoring of blood glucose is an adjunct to the care of persons with diabetes.
The GLUCOMETER ELITE® Diabetes Care System includes the GLUCOMETER ELITE®, GLUCOMETER ELITE® XL Blood Glucose Meters and the GLUCOMETER ELITE® Test Strips. The system is an electrochemical method-based meter and dry reagent sensor (test strips) designed for testing blood glucose by persons with diabetes in the home or by healthcare professionals in healthcare facilities.
The provided text describes the GLUCOMETER ELITE® Diabetes Care System. However, it does not contain specific acceptance criteria (like accuracy percentages or specific ranges) or detailed study outcomes that would fit into a table format as requested. The document is a 510(k) summary focused on demonstrating substantial equivalence to predicate devices, rather than a detailed clinical trial report with specific performance metrics.
Therefore, I cannot provide a table of acceptance criteria and reported device performance with specific numerical values for metrics like accuracy, sensitivity, or specificity.
I can, however, extract the information that is present:
Acceptance Criteria and Reported Device Performance:
Acceptance Criteria | Reported Device Performance |
---|---|
Intended Use | The studies demonstrate that users can obtain blood glucose results from alternate puncture sites that are substantially equivalent to blood glucose results obtained from fingersticks within certain conditions explained in product labeling. |
Linearity | The System has a linear response to glucose from 20-600 mg/dL. |
Equivalence | The clinical evaluation demonstrates that the device can produce blood glucose results from alternate puncture sites that are equivalent to blood glucose results obtained from fingersticks within certain conditions explained in product labeling. |
Here's what can be extracted regarding the study and ground truth, along with limitations due to the nature of the provided document:
-
Sample size used for the test set and the data provenance:
- Sample Size: Not specified in the provided text.
- Data Provenance: The study was conducted "in a clinical setting by persons with diabetes." No country of origin is explicitly mentioned, but the submitter is Bayer Diagnostics in Elkhart, IN, USA, and the FDA approval is for the US market. It's not explicitly stated if it was retrospective or prospective, but clinical studies for device approval are typically prospective.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified.
-
Adjudication method for the test set:
- Not specified.
-
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study was not done. This device is a blood glucose meter, not an AI-powered diagnostic imaging tool that would involve human readers.
-
If a standalone (i.e. algorithm only without human-in-the loop performance) was done:
- The study assessed the device's ability to produce blood glucose results from alternate puncture sites, compared to fingersticks. This is a "standalone" performance assessment in the sense that it's evaluating the device's measurement capability directly, not its interaction with an interpreting human, beyond the user operating the device.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- The "ground truth" for comparison was blood glucose results obtained from fingersticks. This implies that fingerstick measurements (likely taken with a reference method or a predicate device) were considered the standard against which alternate puncture site measurements were compared.
-
The sample size for the training set:
- Not specified. This document describes a clinical performance assessment, not the development and training of a machine learning model. Therefore, the concept of a "training set" in the AI sense does not apply here.
-
How the ground truth for the training set was established:
- Not applicable, as no AI training set is mentioned.
Ask a specific question about this device
Page 1 of 1